Antitumor activity of the selective epid
โ
Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo
๐
Article
๐
2001
๐
John Wiley and Sons
๐
French
โ 216 KB
๐ 1 views
## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressaยฎ (ZD1839) is an orally active, selective EGFRโTKI (epidermal growth factor receptorโtyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell